Clinical Trial Update: Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia [NA]

View source ↗

Summary

A clinical trial is evaluating mesenchymal stem cell therapy for patients with refractory primary immune thrombocytopenia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Mesenchymal stem cell therapy (mesenchymal stem cells)

Snippet

Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Conditions: ITP - Immune Thrombocytopenia | NA | Status: RECRUITING